scholarly journals Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis

2015 ◽  
Vol 206 (2) ◽  
pp. 164-165 ◽  
Author(s):  
Katherine Beck ◽  
John Lally ◽  
Sukhwinder S. Shergill ◽  
Michael A. P. Bloomfield ◽  
James H. MacCabe ◽  
...  
Keyword(s):  
Point Prevalence ◽  
Acute Psychosis ◽  
Aspartate Receptor ◽  
Antibody Titres ◽  
Antibody Positivity ◽  
Treatment Refractory

SummaryN-methyl-d-aspartate receptor (NMDA-R) autoantibodies have been reported in people with acute psychosis. We hypothesised that their presence may be implicated in the aetiology of treatment-refractory psychosis. We sought to ascertain the point prevalence of NMDA-R antibody positivity in patients referred to services for treatment-refractory psychosis. We found that 3 (7.0%) of 43 individuals had low positive NMDA-R antibody titres. This suggests that NMDA-R autoantibodies are unlikely to account for a large proportion of treatment-refractory psychosis.

Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series

2014 ◽  
Vol 160 (1-3) ◽  
pp. 193-195 ◽  
Author(s):  
Michael S. Zandi ◽  
Julia B. Deakin ◽  
Katrina Morris ◽  
Camilla Buckley ◽  
Leslie Jacobson ◽  
...  
Keyword(s):  
Case Series ◽  
Acute Psychosis ◽  
Aspartate Receptor

scholarly journals Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study.

2020 ◽  
Author(s):  
Thomas Waterfield ◽  
Chris Watson ◽  
Rebecca Moore ◽  
Kathryn Ferris ◽  
Claire Tonry ◽  
...  
Keyword(s):  
Cohort Study ◽  
Gastrointestinal Symptoms ◽  
Contact Fatigue ◽  
Final Analysis ◽  
Molecular Testing ◽  
Antibody Testing ◽  
Sense Of Smell ◽  
Antibody Titres ◽  
Previous Infection ◽  
Antibody Positivity

Background Studies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity and timing of testing. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection, and to report the symptomatology of infection in children. Design This multicentre observational cohort study, conducted between 16th April - 3rd July 2020 at 5 UK sites, aimed to recruit 900 children aged 2 to 15 years of age. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms. Results 1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10.1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariate analysis 4 independent variables were identified as significantly associated with SARS-CoV-2 infection. These were: known infected household contact; fatigue; gastrointestinal symptoms; and changes in sense of smell or taste. Discussion In this study children demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. The symptoms of SARS-CoV-2 infection in children were subtle but of those reported, fatigue, gastrointestinal symptoms and changes in sense of smell or taste were most strongly associated with antibody positivity. Registration This study was registered at https://www.clinicaltrials.gov (trial registration: NCT04347408) on the 15/04/2020.

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study

2009 ◽  
Vol 15 (12) ◽  
pp. 1481-1488 ◽  
Author(s):  
Claudia Gneiss ◽  
Pia-Maria Koudouovoh-Tripp ◽  
Stefan Ropele ◽  
Thaddäus Gotwald ◽  
Rainer Ehling ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Interferon Beta ◽  
Previous Treatment ◽  
Neutralizing Antibody ◽  
High Dose ◽  
Continuous Therapy ◽  
High Dose Methylprednisolone ◽  
Antibody Titres ◽  
Antibody Positivity ◽  
To Receive

Neutralizing antibodies against interferon-beta are associated with a reduction of the efficacy of this drug. Continuing treatment leads to a decline or even loss of neutralizing antibodies over years. No strategies are currently available to shorten the period of neutralizing antibody positivity. The objective of this study was to investigate the effect of switching between high and low immunogenic interferon-beta products on neutralising antibody titres. Twenty-four patients treated with the subcutaneously administered interferon-beta 1b or 1a and high titres of neutralizing antibodies were included. At baseline interferon-beta therapy was interrupted for 3 months and two pulses of high dose methylprednisolone were applied. Patients were then randomized to receive either the previous interferon-beta preparation or the low immunogenic intramuscular interferon-beta 1a. The primary end-point was the change of neutralizing antibody titres 12 months after randomization. Twelve patients were switched to interferon-beta 1a intramuscularly and 12 patients remained on previous treatment. Median neutralizing antibody titres were 846 NU at baseline and 196 NU at the end of the study. The median change of neutralizing antibody titres did not differ significantly between therapy switchers and non-switchers. Baseline and final neutralizing antibody titres correlated significantly. In conclusion, neither switching nor continuous therapy with any subcutaneous interferon-beta preparation significantly changed neutralizing antibody titres.

scholarly journals Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

2021 ◽  
Vol 3 (1) ◽  
pp. e000096
Author(s):  
Kushan Karunaratne ◽  
Dariush Ahrabian ◽  
Bernadette Monoghan ◽  
Tom Campion ◽  
Tarek Yousry ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Improvement ◽  
First Line ◽  
Bortezomib Treatment ◽  
Aspartate Receptor ◽  
Nmdar Encephalitis ◽  
Immune Mediated ◽  
Relapsing Remitting ◽  
Treatment Refractory ◽  
Relapsing Remitting Multiple Sclerosis

BackgroundDaclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic andcentral nervous system adverse events. We report a case of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis occurring 14 weeks after stopping daclizumab, which responded to the proteasome inhibitor bortezomib.MethodsFollowing lack of effective clinical response to first line (corticosteroid, plasma exchange, intravenous immunoglobulin) and second line (rituximab) treatments, bortezomib therapy was commenced. The patient received six cycles of bortezomib treatment.ResultsClinical improvement was noted 4 weeks after the first of six cycles of bortezomib and the patient experienced sustained clinical improvement.ConclusionOur case provides further class IV evidence of the use of bortezomib therapy for treatment refractory anti-NMDAR encephalitis.

scholarly journals Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off

2021 ◽  
Author(s):  
Heather J Whitaker ◽  
Charlotte Gower ◽  
Ashley D Otter ◽  
Ruth Simmons ◽  
Freja Kirsebom ◽  
...  
Keyword(s):  
Surveillance Studies ◽  
Assay Performance ◽  
Antibody Titres ◽  
Antibody Positivity ◽  
Serological Surveillance ◽  
Alpha Variant

Serological surveillance studies sometimes use presence of anti-nucleocapsid antibody as a marker of natural SARS-CoV-2 infection. We explore seroconversion rates and antibody titres following Alpha and Delta variant infections, and vaccine breakthrough infections. We find lower seroconversion rates particularly following Alpha-variant vaccine breakthrough infections. We re-evaluate assay performance with a mix of past waned infections and recent breakthrough infections, that is relevant to current serological surveillance.

scholarly journals Acute Psychosis Due to Anti-N-Methyl D-Aspartate Receptor Encephalitis Following COVID-19 Vaccination: A Case Report

2021 ◽  
Vol 12 ◽  
Author(s):  
Patrick Flannery ◽  
Ingrid Yang ◽  
Madjid Keyvani ◽  
George Sakoulas
Keyword(s):  
Cerebrospinal Fluid ◽  
Case Report ◽  
Nmda Receptor ◽  
Young Female ◽  
High Dose ◽  
Acute Psychosis ◽  
Neurological Assessment ◽  
Aspartate Receptor ◽  
Nmdar Encephalitis ◽  
History Of

Anti-N-methyl D-aspartate (NMDA) receptor (anti-NMDAR) encephalitis has been reported after SARS-CoV-2 infection, but not after SARS-CoV-2 vaccination. We report the first known case of anti-NMDAR encephalitis after SARS-CoV-2 immunization in a young female presenting with acute psychosis, highlighting a rare potential immunological complication of vaccination against SARS-CoV-2 that is currently being distributed worldwide. The patient presented initially with anxiety and hypochondriacal delusions which progressed to psychosis and catatonia but returned to baseline with aggressive immunomodulatory therapy consisting of intravenous immunoglobulin, high-dose glucocorticoids, and rituximab. This study highlights that the workup of acute psychosis should include establishing a history of recent vaccination followed by a thorough neurological assessment, including for anti-NMDAR antibodies in blood and cerebrospinal fluid.

scholarly journals Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study

2020 ◽  
pp. archdischild-2020-320558 ◽  
Author(s):  
Thomas Waterfield ◽  
Chris Watson ◽  
Rebecca Moore ◽  
Kathryn Ferris ◽  
Claire Tonry ◽  
...  
Keyword(s):  
Cohort Study ◽  
Multivariable Analysis ◽  
Gastrointestinal Symptoms ◽  
Final Analysis ◽  
Molecular Testing ◽  
Antibody Testing ◽  
Sense Of Smell ◽  
Antibody Titres ◽  
Previous Infection ◽  
Antibody Positivity

BackgroundStudies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity, test timing and selection bias. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection.DesignThis multicentre observational cohort study, conducted between 16 April to 3 July 2020 at 5 UK sites, recruited children of healthcare workers, aged 2–15 years. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms.Results1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10·1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms prior to testing. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariable analysis four independent variables were identified as significantly associated with SARS-CoV-2 seropositivity: known infected household contact OR=10.9 (95% CI 6.1 to 19.6); fatigue OR=16.8 (95% CI 5.5 to 51.9); gastrointestinal symptoms OR=6.6 (95% CI 3.0 to 13.8); and changes in sense of smell or taste OR=10.0 (95% CI 2.4 to 11.4).DiscussionChildren demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. Fatigue, gastrointestinal symptoms and changes in sense of smell or taste were the symptoms most strongly associated with SARS-CoV-2 antibody positivity.Trial registration numberNCT0434740.

Sign in / Sign up

Export Citation Format

Share Document